Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta

Yoon, Sam S.; Schmassmann-Suhijar, Diana; Züber, Michel; Konietzny, P.; Schmassmann, Adrian

doi:10.1093/annonc/mdl140

Cited by 17 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined modality treatment consisting of chemotherapy, radiotherapy, and the antiangiogenic agent thalidomide led in NSCLC patients to excessive toxicity as well as a higher incidence of thromboembolic events [48], as already seen in previous studies in other malignancies. Yoon and coworkers [49] reported that chemotherapy with bevacizumab, irinotecan, 5-fluorouracil, and leucovorin was associated with a high incidence of thromboembolism.…”

Section: Discussionmentioning

confidence: 99%

The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

Kadlec

Skřičková

Merta

et al. 2014

The Scientific World Journal

View full text Add to dashboard Cite

Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. In a large cohort of lung cancer patients we monitored the incidence of venous thromboembolism and we identified groups of patients with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favourably affect their morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

Kadlec

Skřičková

Merta

et al. 2014

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…7,10,11 Thus, we can only speculate that the rapid growth of the AAA might have been induced by the toxic effects of chemotherapy, even though there is only an anecdotal report to support this assumption. 9 Acute cardiac toxicity of 5-fluorouracil is a well-known adverse event, 12 but thrombus formation in a normal aorta 13,14 and aortic dissection 15 represent other and very rare cardiovascular adverse events of chemotherapy. The disturbed synthesis of DNA, collagen, and elastin, release of cytokines, inhibition of smooth muscle cell proliferation, and induction of metalloproteinases are so far predominately hypothetically formulated effects of chemotherapeutics that might induce AAA development.…”

Section: Discussionmentioning

confidence: 99%

Unusual course of an abdominal aortic aneurysm in a patient treated with chemotherapy for gastric cancer

Zanow

Leistner

Ludewig

et al. 2012

Journal of Vascular Surgery

View full text Add to dashboard Cite

Most aortic aneurysms have a degenerative genesis and show a slow expansion over years. Only a few patients with a rapid progression of mycotic or inflammatory aneurysm during some weeks or months have been reported. We report a patient with a rapidly growing symptomatic infrarenal aneurysm with a maximal diameter of 53 mm, which developed over a 5-month period from a normal aorta and did not feature typical signs of degenerative, inflammatory, or mycotic aneurysm. The aneurysm was successfully treated by endovascular repair. A complete shrinking of the aneurysm sac was demonstrated during a few weeks postoperatively. Because the patient received chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for metastatic gastric carcinoma 1 year before the aneurysm occurred, we postulate that chemotherapy induced a rapid expansion of the aorta in this patient.

show abstract

“…77,78 Endothelial damage, reduction of endothelial renewal capacity, exposure of subendothelial collagen, subsequent tissue factor activation and overexpression of proinflammatory cyclooxygenase2 and Eselectin genes all lead to activation of the coagulation pathway, thereby causing intravascular thrombosis. [79][80][81] Scappaticci et al reported the absolute rate of arterial thromboembolic events as 5.5 events per 100 personyears in their popula tion of patients concurrently receiving bevacizumab and chemotherapy. 82 Pereg and Lisher reported that lowdose aspirin effectively prevented cardiovascular complications in patients receiving bevacizumab who were 65 years or older with a prior history of cardiovascular ischemic events.…”

Section: Malignancy Treatment-related Thrombotic Events Chemotherapymentioning

confidence: 99%

Peripheral arterial ischemic events in cancer patients

2010

View full text Add to dashboard Cite

Thromboembolic complications are the second leading cause of death in cancer patients. In contrast to the large body of literature on venous thromboembolism (VTE), relatively few reports have focused on the pathogenesis, incidence, management and outcomes of arterial thromboembolic events in patients with malignancy. The purpose of this article is to review the current literature on the etiology, mechanisms, and prognosis of arterial thromboembolic events in cancer patients and outline appropriate screening and management guidelines that may help lower the rates of morbidity and mortality related to these events.

show abstract

Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta

Cited by 17 publications

References 5 publications

The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

Unusual course of an abdominal aortic aneurysm in a patient treated with chemotherapy for gastric cancer

Peripheral arterial ischemic events in cancer patients

Contact Info

Product

Resources

About